Stuttgart
21.11.25 | 12:48
0,433 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,417 | 0,487 | 22.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | Senzime to Present at Redeye and BioStock Investor Conferences | 232 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / November 11, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF), a leader in solutions for personalized anesthesia, today announced that Philip Siberg, CEO of Senzime, will be presenting... ► Artikel lesen | |
| 03.11. | Nomination Committee for Senzime Annual General Meeting 2026 | 191 | ACCESS Newswire | UPPSALA, SWEDEN / ACCESS Newswire / November 3, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - A Nomination Committee consisting of shareholder representatives has been established for Senzime AB (publ.)... ► Artikel lesen | |
| 29.10. | Senzime Q3 2025: Strong Growth and Clear Steps Towards Profitability | 225 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / October 29, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB's (publ) interim report for January - September 2025 is now available on the company's website www.senzime.com... ► Artikel lesen | |
| 23.10. | Invitation to Presentations of Senzime's Third Quarter 2025 Report | 223 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / October 23, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime invites investors, analysts, and media to a webcast presentation of the third quarter report for 2025 on... ► Artikel lesen | |
| SENZIME Aktie jetzt für 0€ handeln | |||||
| 08.10. | Senzime Launches EMGINE, The Next-Generation Software Suite Advancing Neuromuscular Monitoring | 247 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / October 8, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ) today announced the launch of EMGINETM, a proprietary software suite for its next-generation TetraGraph®... ► Artikel lesen | |
| 03.10. | Senzime Welcomes New European Pediatric Guidelines Recommending EMG-Based Neuromuscular Monitoring | 238 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / October 3, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ) welcomes today's presentation at the ESPA congress in Berlin of the first-ever pediatric guidelines... ► Artikel lesen | |
| 17.09. | Senzime Awarded Contract to Supply the U.S. Department of Defense and Walter Reed National Military Medical Center | 278 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / September 17, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ) today announces that the U.S. Department of Defense has awarded a contract to supply the TetraGraph®... ► Artikel lesen | |
| 12.09. | Senzime to Present at Pareto Securities' 16th Annual Healthcare Conference | 292 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / September 12, 2025 / Senzime AB (Nasdaq Stockholm:SEZI)(OTCQX:SNZZF), a leader in precision-based monitoring during anesthesia, today announced that the company will... ► Artikel lesen | |
| 12.09. | Senzime Launches Integration with Mindray Patient Monitors | 316 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / September 12, 2025 / Senzime AB (publ) today announced the launch of new connectivity solutions to external data platforms, monitors, and electronic health records. The... ► Artikel lesen | |
| 09.09. | Senzime Welcomes New Japanese Guidelines on Neuromuscular Monitoring | 258 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / September 9, 2025 / Senzime AB (publ) (STO:SEZI)(OTCQX:SNZZF) - today announced that the Japanese Society of Anesthesiology (JSA) has published updated clinical guidelines... ► Artikel lesen | |
| 08.09. | Senzime to Present at the European Growth Virtual Investor Conference on September 11 | 237 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / September 8, 2025 / Senzime AB (STO:SEZI)(Nasdaq Stockholm:SEZI)(US OTCQX:SNZZF), a leader in precision-based monitoring of patients undergoing anesthesia, today announced... ► Artikel lesen | |
| 04.09. | Extensive Clinical and Competitive Evaluation Leads Major California University Hospital System to Standardize on Senzime's TetraGraph System | 224 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / September 4, 2025 / Senzime AB (publ) (STO:SEZI)(OTCQX:SNZZF) today announced that one more leading university-based hospital system in California has selected Senzime's... ► Artikel lesen | |
| 05.08. | Senzime Secures TetraGraph Installations Across All Sites of World-Leading US Hospital System | 359 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / August 5, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime today announced another strategic milestone in the U.S., having secured the delivery of its TetraGraph system... ► Artikel lesen | |
| 31.07. | New Number of Shares and Votes in Senzime AB | 322 | ACCESS Newswire | UPPSALA, SWEDEN / ACCESS Newswire / July 31, 2025 / The number of shares and votes in Senzime AB (STO:SEZI)(OTCQX:SNZZF) ("Senzime") has increased during July due to the directed share issue of 700... ► Artikel lesen | |
| 23.07. | Senzime's TetraGraph System Receives Regulatory Approval in Mexico | 318 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / July 23, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime today announced that its TetraGraph system has received approval from the Mexican Secretariat of Health (COFEPRIS)... ► Artikel lesen | |
| 18.07. | Senzime im Q2 2025: Starkes Wachstum im US-Markt treibt Umsatz an | 2 | Investing.com Deutsch | ||
| 18.07. | Senzime Q2 2025 slides: 90% sales growth as US expansion accelerates | 1 | Investing.com | ||
| 18.07. | Senzime: Interim Report April-June 2025: 88% Growth in Local Currency | 531 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / July 18, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB's (publ) interim report for April - June 2025 is now available on the company's website www.senzime.com.Financial... ► Artikel lesen | |
| 09.07. | Senzime's Licensee Fukuda Denshi Expands Market Reach with Regulatory Approvals in the US and UK | 291 | ACCESS Newswire | UPPSALA, SWEDEN / ACCESS Newswire / July 9, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) today announced that its licensee, Fukuda Denshi, has received FDA and UKCA approvals to launch its integrated HN-100... ► Artikel lesen | |
| 08.07. | Invitation to Presentation of Senzime's Second Quarter 2025 Report | 286 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / July 8, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ.) invites investors, analysts, and media to a webcast presentation of the second quarter report for... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 43,360 | +1,98 % | Carl Zeiss Meditec-Aktie mit Aufwärtssignalen - Experten halten große Kursgewinne für möglich! | ||
| ECKERT & ZIEGLER | 15,470 | +0,19 % | BERENBERG stuft ECKERT & ZIEGLER auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Eckert & Ziegler auf "Buy" mit einem Kursziel von 24 Euro belassen. Der Strahlen- und Medizintechnikkonzern habe durchwachsene Zahlen vorgelegt... ► Artikel lesen | |
| UNITEDHEALTH | 277,80 | 0,00 % | UNITEDHEALTH GROUP INC: Jetzt wird's ernst am Markt! | ||
| DRAEGERWERK | 68,30 | 0,00 % | Dreifach-Chance bei Drägerwerk | Die Aktien von Drägerwerk handeln weit unter dem, was möglich wäre. Ein einfacher Vergleich macht das offensichtlich. Der Börsenwert der Stamm- und Vorzugsaktien beträgt zusammen nicht ganz 1,2 Milliarden.... ► Artikel lesen | |
| GERRESHEIMER | 23,560 | 0,00 % | EQS-News: Gerresheimer AG: Science Based Targets Initiative bestätigt CO2e Reduktionsziele | EQS-News: Gerresheimer AG
/ Schlagwort(e): Nachhaltigkeit
Gerresheimer: Science Based Targets Initiative bestätigt CO2e Reduktionsziele
18.11.2025 / 10:02 CET/CEST
Für... ► Artikel lesen | |
| INTUITIVE SURGICAL | 488,85 | +0,26 % | Where Will Intuitive Surgical Stock Be in 10 Years? | ||
| TELADOC HEALTH | 6,029 | -0,30 % | Does Teladoc's Acquisition Strategy Boost Growth and Global Footprint? | ||
| THERMO FISHER | 511,30 | +0,22 % | Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Philadelphia | ||
| ESSILORLUXOTTICA | 308,10 | 0,00 % | EssilorLuxottica reportedly offers to buy 5%-10% stake in Armani | ||
| ROKU | 80,82 | -0,25 % | Roku poised to end in green after seven straight sessions of declines | ||
| HIMS & HERS HEALTH | 30,140 | +0,03 % | Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model | ||
| FAMICORD | 5,250 | -1,87 % | EQS-News: FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung | EQS-News: FamiCord AG
/ Schlagwort(e): 9-Monatszahlen
FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung... ► Artikel lesen | |
| M1 KLINIKEN | 15,900 | -3,17 % | EQS-News: M1 Kliniken AG verzeichnet starkes EBIT-Wachstum von 11% und erzielt Ergebnis je Aktie von 0,86EUR. | EQS-News: M1 Kliniken AG
/ Schlagwort(e): 9-Monatszahlen/Quartalsergebnis
M1 Kliniken AG verzeichnet starkes EBIT-Wachstum von 11% und erzielt Ergebnis je Aktie von 0,86EUR.
18.11.2025... ► Artikel lesen | |
| DEXCOM | 52,60 | +0,57 % | FDA Clears Dexcom Smart Basal, First CGM-Integrated Basal Insulin Dosing Optimizer | WASHINGTON (dpa-AFX) - DexCom, Inc. (DXCM) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has cleared Dexcom Smart Basal, the first and only continuous glucose monitor... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 84,80 | +0,71 % | Analysts project durable growth with many near-term catalysts for Boston Scientific |
Das Unternehmen SENZIME AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,433 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENZIME AB finden Sie auf Wallstreet Online.